MGTA - Magenta Therapeutics bluebird bio team up for MGTA-145 combo trial in sickle cell disease

Magenta Therapeutics (MGTA) and bluebird bio (BLUE) have entered into clinical trial collaboration to evaluate MGTA-145, a CXCR2 agonist, in combination with plerixafor, a CXCR4 antagonist, for mobilization and collection of stem cells in patients with sickle cell disease.Under the collaboration, Magenta will undertake preclinical studies and both the companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.Recently completed Phase 1 study in healthy volunteers, showed that MGTA-145, in combination with plerixafor can rapidly and reliably mobilize high numbers of functional stem cells in a single day, without the need for granulocyte-colony stimulating factor, a commonly used mobilization agent.MGTA shares are up 3% in premarket.

For further details see:

Magenta Therapeutics, bluebird bio team up for MGTA-145 combo trial in sickle cell disease